Novo Nordisk (NVO) has received FDA approval for its oral GLP-1 pill for weight management, expected to launch in early 2026. This is a significant development as it offers a non-injection alternative, potentially broadening market access. The company is projected to capture a substantial share of the weight loss drug market. Despite a recent dip in stock price and a slight expected slowdown in revenue growth for the next quarter, the company's strong patent protection, innovative pipeline, and solid free cash flow suggest a positive outlook. The stock is currently trading at a reasonable forward P/E ratio, making it an attractive investment.